JPMorgan raised the firm’s price target on Amicus (FOLD) to $18 from $16 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect a December 2026 target versus 2025 previously.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus Therapeutics Reports Strong Growth Amid Strategic Advances
- Strong Growth and Strategic Expansion Drive Buy Rating for Amicus Therapeutics
- Amicus Therapeutics: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Amicus Therapeutics Reports Strong Q2 2025 Growth
- Amicus Therapeutics: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating